Prokidney (PROK) EBITDA (2021 - 2026)
Prokidney (PROK) reported EBITDA of -$44.9 million for Q1 2026, down 8.57% year-over-year from -$49.1 million in Q1 2025, and down 151.13% on a QoQ basis from $87.9 million in Q4 2025.
Prokidney (PROK) has 6 years of EBITDA data on file, last reported at -$44.9 million in Q1 2026.
- Quarterly EBITDA fell 8.57% year-over-year to -$44.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.3 million (up 80.92% YoY) and the FY2025 annual result came in at -$31.8 million, up 82.71% from the prior year.
- EBITDA fell to -$44.9 million in Q1 2026 per PROK's latest filing, from $87.9 million in the prior quarter.
- Across five years, EBITDA topped out at $87.9 million in Q4 2025 and bottomed at -$66.5 million in Q1 2022.
- The 5-year median for EBITDA is -$40.1 million (2024), against an average of -$33.2 million.
- The widest annual swing landed in 2022, when EBITDA slumped 1282455.0%; it then soared 270.41% in 2025.
- Tracing PROK's EBITDA over 5 years: stood at -$30.2 million in 2022, then rose by 19.93% to -$24.2 million in 2023, then tumbled by 113.02% to -$51.6 million in 2024, then soared by 270.41% to $87.9 million in 2025, then slumped by 151.13% to -$44.9 million in 2026.
- Per Business Quant, the three latest PROK EBITDA figures stand at -$44.9 million (Q1 2026), $87.9 million (Q4 2025), and -$38.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - | -44.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.93 Mn |
| Dec 31, 2025 | 87.88 Mn |
| Sep 30, 2025 | -38.54 Mn |
| Jun 30, 2025 | -39.71 Mn |
| Mar 31, 2025 | -41.39 Mn |
| Dec 31, 2024 | -51.57 Mn |
| Sep 30, 2024 | -48.97 Mn |
| Jun 30, 2024 | -43.06 Mn |
| Mar 31, 2024 | -40.08 Mn |
| Dec 31, 2023 | -24.21 Mn |
| Sep 30, 2023 | -46.62 Mn |
| Jun 30, 2023 | -39.82 Mn |
| Mar 31, 2023 | -40.88 Mn |
| Dec 31, 2022 | -30.24 Mn |
| Sep 30, 2022 | -35.57 Mn |
| Jun 30, 2022 | -20.74 Mn |
| Mar 31, 2022 | -66.46 Mn |
| Dec 31, 2021 | -2.33 Mn |
| Sep 30, 2021 | -17.08 Mn |
| Jun 30, 2021 | -5,325.00 |
| Mar 31, 2021 | -5,182.00 |